 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 GLOBE NEWSWIRE -- Royalty Pharma Nasdaq: RPRX, BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX and Athyrium Capital Management, LP today announced transactions totaling 325 million in funding for BioCryst, with 250 million available at closing, to support the launch of ORLADEYOTM berotralstat in hereditary angioedema HAE and the development of its oral Factor D inhibitor, BCX9930. 